
The clinical success of zzso zzso zzso zzso in patients with lung cancer is limited by the inevitable development of treatment zzso Two reports in this issue of Cancer Discovery uncover additional mechanisms by which zzso lung zzso escape from zzso zzso inhibitor zzso These findings pave the way for clinical testing of new rational therapeutic strategies to prevent or overcome resistance to zzso zzso zzso in the zzso 

